Search

The therapeutic landscape of metastatic prostate cancer has undergone a profound revolution in recent years. In addition to the introduction of novel molecules in the clinics, the field has witnessed a tremendous development of functional imaging modalities adding new biological insights which can ultimately inform tailored treatment strategies, including local therapies. The evolution and rise of Stereotactic Body Radiotherapy (SBRT) have been particularly notable in patients with oligometastatic disease, where it has been demonstrated to be a safe and effective treatment strategy yielding favorable results in terms of disease control and improved oncological outcomes. The possibility of debulking all sites of disease, matched with the ambition of potentially extending this treatment paradigm to polymetastatic patients in the not-too-distant future, makes Biology-guided Radiotherapy (BgRT) an attractive paradigm which can be used in conjunction with systemic therapy in the management of patients with metastatic prostate cancer. [ABSTRACT FROM AUTHOR]

This document discusses the investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) in the treatment of metastatic kidney cancer. The article highlights the increasing incidence of renal cell carcinoma (RCC) in the older population and the challenges of offering invasive therapies to elderly patients. SABR has emerged as a noninvasive alternative, with studies showing promising results in terms of oncologic outcomes and renal function preservation. The document also mentions ongoing clinical trials investigating the combination of SABR with immune checkpoint inhibitors and tyrosine kinase inhibitors. The authors emphasize the advancements in radiation oncology and radiobiology that have made precise delivery of high-dose radiation possible, and they anticipate the availability of new radiotracers and treatment modalities in this field. [Extracted from the article]